Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

442 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. Among authors: kesselheim as. JAMA. 2018 Jun 19;319(23):2373-2374. doi: 10.1001/jama.2018.7424. JAMA. 2018. PMID: 29800027 No abstract available.
University-based science and biotechnology products: defining the boundaries of intellectual property.
Kesselheim AS, Avorn J. Kesselheim AS, et al. JAMA. 2005 Feb 16;293(7):850-4. doi: 10.1001/jama.293.7.850. JAMA. 2005. PMID: 15713775
The pharmaceutical and biotechnology industries have long relied on patenting as the primary means of allocating ownership and control over new discoveries. ...
The pharmaceutical and biotechnology industries have long relied on patenting as the primary means of allocating ownership and contro …
The swinging pendulum: the Supreme Court reverses course on ERISA and managed care.
Kesselheim AS, Brennan TA. Kesselheim AS, et al. Yale J Health Policy Law Ethics. 2005 Winter;5(1):451-63. Yale J Health Policy Law Ethics. 2005. PMID: 15742588 No abstract available.
Overbilling vs. downcoding--the battle between physicians and insurers.
Kesselheim AS, Brennan TA. Kesselheim AS, et al. N Engl J Med. 2005 Mar 3;352(9):855-7. doi: 10.1056/NEJMp058011. N Engl J Med. 2005. PMID: 15745973 No abstract available.
Biomedical patents and the public's health: is there a role for eminent domain?
Kesselheim AS, Avorn J. Kesselheim AS, et al. JAMA. 2006 Jan 25;295(4):434-7. doi: 10.1001/jama.295.4.434. JAMA. 2006. PMID: 16434634 No abstract available.
The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
Kesselheim AS, Fischer MA, Avorn J. Kesselheim AS, et al. Health Aff (Millwood). 2006 Jul-Aug;25(4):1095-102. doi: 10.1377/hlthaff.25.4.1095. Health Aff (Millwood). 2006. PMID: 16835191
We use it as a case study to assess how FDA standards for drug approval, marketing practices by drug manufacturers, and physicians' prescribing choices can shape the risk-benefit relationship of new drugs. ...
We use it as a case study to assess how FDA standards for drug approval, marketing practices by drug manufacturers, and physicians' p …
The role of litigation in defining drug risks.
Kesselheim AS, Avorn J. Kesselheim AS, et al. JAMA. 2007 Jan 17;297(3):308-11. doi: 10.1001/jama.297.3.308. JAMA. 2007. PMID: 17227983 No abstract available.
442 results
Jump to page
Feedback